WASHINGTON, Feb 8 (Reuters) - Optimer Pharmaceuticals Inc., a development stage company, on Thursday cut the expected price of its planned initial public offering to $8 to $9 per share from a previous range of $12 to $14.
WASHINGTON, Feb 8 (Reuters) - Optimer Pharmaceuticals Inc., a development stage company, on Thursday cut the expected price of its planned initial public offering to $8 to $9 per share from a previous range of $12 to $14.
